Fluvastatin mitigates SARS-CoV-2 infection in human lung cells.

ABSTRACT: Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Quantitative proteomics revealed that fluvastatin and other tested statins modulated the cholesterol synthesis pathway without altering innate antiviral immune responses in infected lung epithelial cells. However, fluvastatin treatment specifically downregulated prote

SUBMITTER: Zapatero-Belinchon FJ 

PROVIDER: S-EPMC8599137 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature